For reference: oral semaglutide · STEP 2.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
Can someone derive this rather than assert it?
Mechanically, the mechanism question has a clean answer for the peripheral effects and a much less clean answer for the central ones, and it is worth being explicit about which of those you are asking about.
Receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
On the detail: comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.
Retatrutide’s Phase 2 dose-ranging results reported dose-dependent weight reduction with a tri-agonist across a range of doses, and the magnitude at the top dose is what motivated the Phase 3 TRIUMPH programme[1].
The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.
edited 27 Apr 2026 by deamidation_watch — corrected a unit error in the worked example
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsGLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.
The GIP agonism-versus-antagonism question remains open, and the awkward fact is that both directions have produced weight loss in humans. The reconciling hypothesis is that chronic GIPR agonism produces receptor desensitisation and therefore functions as a pharmacological antagonist, but that is a hypothesis fitted to the data rather than an independent finding.
It helps to be literal here: what the glucagon arm of a tri-agonist adds is energy expenditure and hepatic fat mobilisation; what it costs is glycaemic control and an increase in heart rate. That is why the tri-agonists show a steeper weight-loss curve and why their development requires more care around cardiac and glycaemic endpoints than a pure GLP-1 agonist does.
The role of the area postrema and the hypothalamic arcuate nucleus in GLP-1-mediated appetite suppression is supported by both the neuroanatomy of receptor expression and by the effect of lesioning studies in animal models.
If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.
Put another way, start from the receptor and the rest follows: which receptors, in what ratio, with what signalling bias, reached at what concentration.
The Aib substitution at position 8 replaces alanine with α-aminoisobutyric acid, which is sterically hindered enough that dipeptidyl peptidase-4 cannot cleave the N-terminal dipeptide. That single change takes the half-life from minutes to hours. The C18 diacid on a linker at Lys26 then binds albumin reversibly, which both shields the molecule from renal filtration and creates a depot that releases slowly — taking hours to about a week.
Oral bioavailability of a 4 kDa peptide is essentially zero without help. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, which raises local gastric pH and transiently increases transcellular permeability in a small area of gastric mucosa. It works, and it delivers roughly one per cent of the dose, which is why the oral tablet strengths are an order of magnitude above the injectable and why fasting and water volume are not optional details.
Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.
Two structural interventions do the work: substitution at the DPP-4 cleavage site to stop enzymatic degradation, and a fatty-acid chain to bind serum albumin and create a slowly released reservoir. Remove either and you are back to a compound requiring continuous infusion.
Tirzepatide is an imbalanced dual agonist: it is more potent at the GIP receptor than at the GLP-1 receptor, which is the opposite of what most people assume from the way it is described. Whether the GIP contribution works through central appetite pathways, through adipose insulin sensitisation, or through modulating the GLP-1 signal is genuinely unsettled, and the honest position is that the clinical result is clear and the attribution is not.
Do not convert doses between agents. There is no exchange rate, and constructing one is how people arrive at an order-of-magnitude error.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.